Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models

Cancer Science

Volumn 106, Issue 5, 2015, Pages 627-634

  Yamamoto, Yoshiyuki ^a,b   Hyodo, Ichinosuke ^b   Koga, Yoshikatsu ^a   Tsumura, Ryo ^a   Sato, Ryuta ^a   Obonai, Toshihumi ^a   Fuchigami, Hirobumi ^a   Furuya, Fumiaki ^a   Yasunaga, Masahiro ^a   Harada, Mitsunori ^c   Kato, Yasuki ^c   Ohtsu, Atsushi ^d   Matsumura, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c Research Division   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

Author keywords

Antibody drug conjugate; Drug delivery system; Epirubicin; Polymeric micelles; Tissue factor

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; THROMBOPLASTIN; TISSUE FACTOR MONOCLONAL ANTIBODY CONJUGATED EPIRUBICIN INCORPORATING POLYMERIC MICELLE; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; MICELLE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MICELLE; MOUSE; NONHUMAN; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG SCREENING; IMMUNOLOGY; METABOLISM; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; EPIRUBICIN; FEMALE; HUMANS; IMMUNOCONJUGATES; MICE, INBRED BALB C; MICELLES; THROMBOPLASTIN; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929704775     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12645     Document Type: Article

References (45)

1. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-91.
2. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183-9.
3. Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30: 2190-6.
4. Junutula JR, Raab H, Clark S et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26: 925-32.
5. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.
6. Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y. Block-copolymer micelles as vehicles for drug delivery. J Control Release 1993; 24: 119-32.
7. Hamaguchi T, Matsumura Y, Suzuki M et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005; 92: 1240-6.
8. Hamaguchi T, Kato K, Yasui H et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 2007; 97: 170-6.
9. Kato K, Chin K, Yoshikawa T et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs 2012; 30: 1621-7.
10. Nishiyama N, Okazaki S, Cabral H et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 2003; 63: 8977-83.
11. Uchino H, Matsumura Y, Negishi T et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 2005; 93: 678-87.
12. Plummer R, Wilson RH, Calvert H et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer 2011; 104: 593-8.
13. Harada M, Bobe I, Saito H et al. Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. Cancer Sci 2011; 102: 192-9.
14. Takahashi A, Yamamoto Y, Yasunaga M et al. NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci 2013; 104: 920-5.
15. Yamamoto Y, Hyodo I, Takigahira M et al. Effect of combined treatment with the epirubicin-incorporating micelles (NC-6300) and 1, 2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) on a human gastric cancer model. Int J Cancer 2014; 135: 214-23.
16. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012; 119: 924-32.
17. Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 5th edn. Philadelphia, USA: Lippincott Williams & Wilkins, 2006.
18. Saito Y, Hashimoto Y, Kuroda J et al. The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody. Eur J Cancer 2011; 47: 2230-9.
19. Zhao J, Mi Y, Feng SS. Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. Biomaterials 2013; 34: 3411-21.
20. Sawant RR, Jhaveri AM, Torchilin VP. Immunomicelles for advancing personalized therapy. Adv Drug Deliv Rev 2012; 64: 1436-46.
21. Li W, Zhao H, Qian W et al. Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials 2012; 33: 5349-62.
22. Yue J, Liu S, Wang R et al. Fluorescence-labeled immunomicelles: preparation, in vivo biodistribution, and ability to cross the blood-brain barrier. Macromol Biosci 2012; 12: 1209-19.
23. Taylor RM, Sillerud LO. Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner. Int J Nanomedicine 2012; 7: 4341-52.
24. Liao C, Sun Q, Liang B, Shen J, Shuai X. Targeting EGFR-overexpressing tumor cells using Cetuximab-immunomicelles loaded with doxorubicin and superparamagnetic iron oxide. Eur J Radiol 2011; 80: 699-705.
25. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 2003; 100: 6039-44.
26. Jin C, Qian N, Zhao W et al. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma. Biomacromolecules 2010; 11: 2422-31.
27. Pirollo KF, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol 2008; 26: 552-8.
28. Kirpotin DB, Drummond DC, Shao Y et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006; 66: 6732-40.
29. Mamot C, Drummond DC, Noble CO et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005; 65: 11631-8.
30. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007; 104: 15549-54.
31. Choi CH, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 2010; 107: 1235-40.
32. Koenders PG, Peters WHM, Wobbes T, Beex LVAM, Nagengast FM, Benraad TJ. Epidermal growth-factor receptor levels are lower in carcinomatous than in normal colorectal tissue. Br J Cancer 1992; 65: 189-92.
33. Messersmith W, Oppenheimer D, Peralba J et al. Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. Cancer Biol Ther 2005; 4: 1381-6.
34. Check Hayden E. Cancer complexity slows quest for cure. Nature 2008; 455: 148.
35. Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J Cell Physiol 2009; 220: 538-47.
36. Collins BE, Blixt O, Han S et al. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J Immunol 2006; 177: 2994-3003.
37. Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother 2008; 57: 1879-90.
38. Burke PJ, Senter PD, Meyer DW et al. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. Bioconjug Chem 2009; 20: 1242-50.
39. Coyne CP, Jones T, Pharr T. Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma. Bioorg Med Chem 2011; 19: 67-76.
40. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
41. Yasunaga M, Manabe S, Tarin D, Matsumura Y. Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Bioconjug Chem 2011; 22: 1776-83.
42. Matsumura Y. Cancer stromal targeting (CAST) therapy. Adv Drug Deliv Rev 2012; 64: 710-9.
43. Hisada Y, Yasunaga M, Hanaoka S et al. Discovery of an uncovered region in fibrin clots and its clinical significance. Sci Rep 2013; 3: 2604.
44. Kothari H, Pendurthi UR, Rao LV. Analysis of tissue factor expression in various cell model systems: cryptic vs. active. J Thromb Haemost 2013; 11: 1353-63.
45. Song HB, Park KD, Kim JH, Kim DH, Yu YS, Kim JH. Tissue factor regulates tumor angiogenesis of retinoblastoma via the extracellular signal-regulated kinase pathway. Oncol Rep 2012; 28: 2057-62.